Phone-based artificial intelligence tool for monitoring women with gestational diabetes
Tests an AI phone tool for teaching and monitoring women with gestational diabetes.
Key facts
- Who runs it
- JOSE FERNANDO VILELA-MARTIN
- Where
- Brazil1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Artificial Intelligence and Gestacional Diabetes
- Status
- Enrolling by invitation
- People taking part
- 100 people, planned
- Started
- 1 Jun 2024
- Expected to end
- 20 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- monitoring model for women with gestacional diabetes using pharmacological therapy
- Record updated
- 15 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with gestational diabetes (diabetes that starts in pregnancy). It tests an AI phone tool that helps monitor blood sugar and gives education.
- Age
- 18 Years to 40 Years
- Sex
- Women only
- Disease stage
- Gestational diabetes, with the pregnancy at up to 28 weeks and 6 days.
Main reasons for not taking part
- Pregnancy longer than 28 completed weeks at the first visit
- Diabetes that was already clear before or outside pregnancy (fasting glucose > 126 mg/dl (7 mmol/L) or after-meal glucose > 200 mg/dl (11.1 mmol/L))
- Pregnancy outcome is not known
This trial only enrols pregnant participants. The registry sentence this rests on: Gestacional diabetes women with gestational age of up to 28 weeks and 6 days
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Gestacional diabetes women with gestational age of up to 28 weeks and 6 days
- Gestacional diabetes women who sign the free and informed consent form
Who cannot take part
- Participants with overt DM (fasting glucose > 126 mg/dl or postprandial > 200 mg/dl)
- Gestational age greater than 28 completed weeks at the first consultation
- Unknown outcome
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Artificial intelligence (AI) technology can assist medical teams in remote monitoring and continuing education of women with gestational diabetes (GDM), potentially improving adherence to interventions and impacting outcomes. An AI remote monitoring model called "monitoring model for women with GDM using pharmacological therapy," created by the ChamouDr technical team, will be analyzed focusing on disease education, glycemic control monitoring, and therapeutic interventions. Women diagnosed with GDM are invited to participate in the study and sign a free and informed consent form. The AI tool is installed on the pregnant woman's cell phone, who receives instructions to collect capillary blood glucose 6 times a day according to the protocol, at home, and report the results via WhatsApp to the study tool. Algorithm generated by the AI model based on self monitoring of blood glucose (SMBG) informs about diabetes control in the last week. The dashboard is accessible via a web browser, and signals: in green and red for patients with satisfactory and unsatisfactory control, respectively. Thus, the AI model optimizes the team's time in analyzing and treating patients appropriately in a simple, cost-effective, and accessible way.
The 2 groups in the trial
- Device group: Case group (AI model use)Treatment being tested
Case group - Device group. AI model to monitor glucose control and send education to treat women with gestacional diabetes in insulin treatment.
Treatment: monitoring model for women with gestacional diabetes using pharmacological therapy
- Control group (no use of AI model)No study treatment, for comparison
No device group: Control group - women with gestacional diabetes in insulin treatment under conventional treatment, without the AI model use.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Artificial Intelligence in Education and Monitoring Women With Gestational Diabetes
- Plain-language title
- Phone-based artificial intelligence tool for monitoring women with gestational diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07345143, who can take part
- Record updated
- 15 January 2026